Associated Papers
Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44.
Sohn SH et al.
Cancers, 2022
35884507 (PubMed )
Supplement: cancers-14-03444-s001.zip › supplementary_material_Table_S1.xlsx › SNU638
Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.
Novkovic M et al.
European Journal of Clinical Pharmacology, 2018
Assessing the capability of massively parallel sequencing for opportunistic pharmacogenetic screening.
Ng D et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2017
27537706 (PubMed )
Supplement: NIHMS802548-supplement-Table_S4.pdf
Association of CYP2C19*2 and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients.
Lim JS et al.
British Journal of Clinical Pharmacology, 2016
Molecular mechanisms of genetic variation and transcriptional regulation of CYP2C19.
Helsby NA et al.
Frontiers in Genetics, 2012
Identification of new CYP2C19 variants exhibiting decreased enzyme activity in the metabolism of S-mephenytoin and omeprazole.
Lee SJ et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2009
The human cytochrome P450 Allele Nomenclature Committee Web site: submission criteria, procedures, and objectives.
Sim SC et al.
Methods in Molecular Biology (clifton, N.j.), 2006
Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.
Goldstein JA
British Journal of Clinical Pharmacology, 2001
The Human Cytochrome P450 Allele Nomenclature Committee Web Site : Submission Criteria, Procedures, and Objectives.
Sim SC et al.
Methods in Molecular Biology (clifton, N.j.), 0
Select a paper to view details